Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myo-Inositol in Colitis-Associated Dysplasia
NCT01111292Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) and dysplasia comparing Myo-inositol with Placebo (2 arms). Primary endpoint: Effect of Myo-inositol on P-beta-catenin Staining in Areas of Low Grade Dysplasia at 90 days. Started Oct 2010; status: terminated.
02
Drugs
myo-inositol
03
Conditions
colorectal cancer (CRC)dysplasia
Beyond the preview
Go deeper on NCT01111292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111292.